Marked Chart Marked Chart Closed

The Marked Chart Wire · Series of events

Series of events · Novo Nordisk

Novo Nordisk raises outlook, then faces eye safety reports

Novo Nordisk lifted its financial forecast after strong sales, followed by Danish reports of eye issues in patients.

3 eventsNov 4 to Nov 20NVO-1.4%

Updated

The flow in 3 points

  1. Wegovy pill sales surpassed estimates in the latest quarter
  2. Full-year financial outlook was raised on strong demand
  3. 31 Danish patients reported suspected ocular injuries

What happened, in order

Times are Eastern
  1. Where it began

    Earnings beat

    Novo Nordisk reported quarterly earnings that exceeded expectations, driven by Wegovy pill sales that surpassed estimates.

    Read the story
  2. Outlook raised

    Novo Nordisk improved its financial outlook, citing sustained demand for its obesity treatments Wegovy and Ozempic.

    Read the story
  3. Latest

    Eye issues reported

    Regulators in Denmark are treating 31 individuals who reported suspected ocular injuries associated with a Novo Nordisk medication.

    Read the story

How they connect

The company first reported strong earnings and then raised its full-year outlook based on demand for its weight loss drugs. This was followed by reports from Denmark regarding suspected eye injuries in patients using the company's medication.

The stocks in this series

  1. NVO-1.4%Novo Nordisk A/S$38.87

Prices from Before the open · based on Thu close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.

A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.